🔹 Revenue: DKK 78.1B (Est: DKK78.7B) 😐; +19% YoY
🔹 Net Profit: DKK 29.0B (Est: DKK27.9B) 🟢
🔹 Wegovy: DKK 17.4B (Est: DKK19.0B) 🔴
🔹 Ozempic: DKK 32.7B (Est: DKK32.3B) 🟢
FY25 Guide:
🔹 Cuts Revenue Growth (cc): Now +13–21% vs. prior +16–24% 🔴
🔹 Maintained Operating Profit Growth (cc): +16–24%
Q1 Segment Performance
🔹 US Revenue: +20% YoY
🔹 Obesity Revenue: +67% YoY
🔹 Insulin Revenue: +13% YoY
🔹 Rare Disease Revenue: +5% YoY
🔹 Free Cash Flow: DKK 10B (+89% YoY)
🔸 CEO: ~1/3 of US obesity market now held by GLP-1 compounders
🔸 CFO: Expects 2H utilization step-up for Wegovy and potential label expansion in Q3
🔸 GLP-1 penetration impacted by rapid compounding expansion in the US
🔸 Actively addressing unlawful and unsafe compounding practices